Get the app
US › Healthcare

Lisata Therapeutics Inc. (LSTA)

US · Healthcare · Biotechnology

$1.74+18.37%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-2.9M
EPS
$-0.54

Key statistics

Market cap
$14.7M
Forward P/E
2.7
P/B
1.80
Book value
$0.90
EPS (TTM)
$-1.64
52-week high
$5.07
52-week low
$0.99
50-day MA
$1.93
200-day MA
$3.12
Beta
0.94

Analyst view

Analysts rate Lisata Therapeutics Inc. a buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $4.00.

Shareholding

Insiders
26.24%
Institutions
12.04%

Largest institutional holders

FundStake
Vanguard Capital Management, LLC3.02%
Renaissance Technologies Corp1.46%
Deltec Asset Management LLC0.92%
Geode Capital Management, LLC0.79%
Css LLC0.69%
BlackRock Inc0.61%
Virtu Financial LLC0.47%
Vanguard Fiduciary Trust Co0.39%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lisata Therapeutics Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.